biostudies-literatureSantos Bravo MCIBER Enfermedades InfecciosasGilead Sciencese0244822https://www.ebi.ac.uk/biostudies/studies/S-EPMC9769853biostudies-literatureUnknown10(6)Remdesivir (RDV) was the first antiviral drug approved by the FDA to treat severe coronavirus disease-2019 (COVID-19) patients. RDV inhibits SARS-CoV-2 replication by stalling the non structural protein 12 (nsp12) subunit of the RNA-dependent RNA polymerase (RdRp). No evidence of global widespread RDV-resistance mutations has been reported, however, defining genetic pathways to RDV resistance and determining emergent mutations prior and subsequent antiviral therapy in clinical settings is necessary. This study identified 57/149 (38.3%) patients who did not respond to one course (5-days) (<i>n</i> = 36/111, 32.4%) or prolonged (5 to 20 days) (<i>n</i> = 21/38, 55.3%) RDV therapy by subgenomic RNA detection. Genetic variants in the <i>nsp12</i> gene were detected in 29/49 (59.2%) non respondMicrobiology spectrumGenetic Study of SARS-CoV-2 Non Structural Protein 12 in COVID-19 Patients Non Responders to Remdesivir.PMC9769853IN-ES-540-6089CB21/13/00081Sanchez Palomino SVillanueva JLPuerta PAlonso RVergara AMosquera Gutierrez MDMRodriguez CVila JDiez-Fuertes FCastro PSanzo Machuca ASimarro Redon ARubio ECuesta GHurtado JCSoriano AMarcos MAMartinez MJAlcami JSoria DTuset MFernandez Aviles FBodro MGarcia CSantos Bravo MfalseGenetic Study of SARS-CoV-2 Non Structural Protein 12 in COVID-19 Patients Non Responders to Remdesivir.Remdesivir (RDV) was the first antiviral drug approved by the FDA to treat severe coronavirus disease-2019 (COVID-19) patients. RDV inhibits SARS-CoV-2 replication by stalling the non structural protein 12 (nsp12) subunit of the RNA-dependent RNA polymerase (RdRp). No evidence of global widespread RDV-resistance mutations has been reported, however, defining genetic pathways to RDV resistance and determining emergent mutations prior and subsequent antiviral therapy in clinical settings is necessary. This study identified 57/149 (38.3%) patients who did not respond to one course (5-days) (<i>n</i> = 36/111, 32.4%) or prolonged (5 to 20 days) (<i>n</i> = 21/38, 55.3%) RDV therapy by subgenomic RNA detection. Genetic variants in the <i>nsp12</i> gene were detected in 29/49 (59.2%) non respond2022-01-01T00:00:00Z2022 Dec2026-05-28T21:31:04.738Z2024-12-04T05:13:01.667ZS-EPMC97698533635432010.1128/spectrum.02448-22